Vertex Raises 2024 Revenue Forecast
This is a Vertex news story, published by Yahoo Finance, that relates primarily to Vertex Pharmaceuticals news.
Vertex news
For more Vertex news, you can click here:
more Vertex newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Vertex Pharmaceuticals. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest CF drug Trikafta news, CF treatments news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
cystic fibrosisReuters
•Vertex Pharma lifts annual revenue forecast on cystic fibrosis treatments strength
82% Informative
Vertex Pharmaceuticals raised its annual revenue forecast after beating third-quarter estimates.
Cystic fibrosis is a genetic disorder that affects the lungs, digestive system and other organs.
Vertex 's top-selling CF drug Trikafta rose more than 13% to $2.59 billion for the quarter ended Sept. 30 .
VR Score
92
Informative language
98
Neutral language
72
Article tone
formal
Language
English
Language complexity
59
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links